ZEDENOLEUCEL

MT-401 MULTI-TUMOR-ASSOCIATED ANTIGEN (TAA) SPECIFIC T LYMPHOCYTES. THE MANUFACTURING PROCESS SELECTIVELY AMPLIFIES TUMORTARGETED T CELL PRECURSORS EX VIVO USING ANTIGEN PRESENTING CELLS (APCS) EXPRESSING A RANGE OF TAAS THAT ARE SELECTIVELY OVEREXPRESSED ON LEUKEMIC CELLS. THE STIMULATION IS PERFORMED USING ASEPTIC METHODS AND CLINICAL GRADE PEPTIDE MIXTURES. DONOR T CELLS ARE CULTURED WITH AUTOLOGOUS APCS LOADED WITH THE PEPTIDE MIXTURES SPANNING THE ENTIRE PRIMARY SEQUENCES OF THE FOUR TUMOR ASSOCIATED ANTIGENS PRAME, NY-ESO-1, SURVIVIN, AND WT1 IN THE PRESENCE OF RECOMBINANT CYTOKINES TO STIMULATE T CELL GROWTH zedenoleucel [INN] ZEDENOLEUCEL [USAN]